multicellular

(redirected from Multicell)
Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

multicellular

 [mul″tĭ-sel´u-ler]
composed of many cells.

mul·ti·cel·lu·lar

(mŭl'tē-sel'yū-lăr),
Composed of many cells.

multicellular

(mŭl′tē-sĕl′yə-lər, -tī-)
adj.
Having or consisting of many cells: multicellular organisms.

mul′ti·cel′lu·lar′i·ty (-lăr′ĭ-tē) n.

multicellular

[-sel′yələr]
1 consisting of more than one cell.
2 containing many cavities.

multicellular

composed of many cells. see ACELLULAR.

multicellular

composed of many cells.
References in periodicals archive ?
The new Luwa MultiCell Filter MCV opens up many opportunities to reduce the required floor space of air conditioning and filtration plants in textile mills and offers the following advantages:
The high level of functionality included in the multiCELL unit can be expanded easily, by adding additional hardware and software modules.
Product profiles for late stage and clinical stage products of MultiCell Technologies, Inc.
MultiCell intends to use its human liver cell and liver stem cell assets to identify therapeutic targets and new drug candidates specifically targeting the treatment of primary liver cancer and intrahepatic bile duct cancer," said Jerry Newmin, Chairman & CEO of MultiCell Technologies.
In addition to the aforementioned convertible debentures, MultiCell granted LJCI a warrant to purchase up to 10 million shares of Rule 144 Common Stock at a strike price of $1.
The patent portfolio, granted to MultiCell by RIH as part of the original agreement between the two entities, includes a method for isolating and immortalizing a population of primary hepatocytes (liver cells) that are high in P450 enzymes.
The new Luwa MultiCell Filter reduces the required floor space of air conditioning and filtration plants in textile mills.
From its inception, MultiCell has been committed to competing on the international stage," said Dr.
If MCT-125 is approved for the treatment of fatigue in MS patients by the MHRA, the FDA, and other such regulatory agencies, and is successfully commercialized, MultiCell estimates MCT-125 could generate up to $3 billion in cumulative worldwide sales during the time MCT-125 is under patent protection.
MultiCell Technologies Inc (OTCBB: MCET), a clinical-stage biopharmaceutical company, said on Wednesday that at the 2012 American Society for Cell Biology (ASCB) Annual Meeting, being held in San Francisco, California, Simona Bot, MD on Tuesday presented preclinical research results in an abstract titled 'Short Synthetic Double Stranded RNA with Dual Activity - Oncolytic and Immune Modulatory - for Hepatocellular Carcinoma'.
MultiCell has scheduled a meeting with the MHRA for December 1, 2006, to present the company's clinical development plan for the Phase IIb of MCT-125.
An electric shock of chemical stimulation encouraged the reconstituted eggs to start dividing into multicell embryos.